We would love to hear your thoughts about our site and services, please take our survey here.
Just shows how ridiculously undervalued we are. With SRA737 proven in the clinic and can deal with half of all solid tumour cancers - and SDC1801 can potentially treat up to at least 39 Autoimmune diseases plus covid and pneumonia. If we were still in pennies it would have been at least 6p - not this ridiculous price resulting from consolidation which was just a ploy to give cheap shares to PH Clients.
Gunner - Confused by your use of the term “nothing happening for a while” which can be just a very short time or longer depending on context. In Sareum’s situation the term would apply to early January when Sierra Oncology are required to return SRA 737 back to the Cancer Pioneer Fund. Stephen Parker confirmed that several pharmaceuticals had already expressed interest in SRA 737s future development.§
I am not convinced of your motive here - did you get caught on the hop on Friday with the sudden increase in the share price following the very positive news at the AGM?
https://aacrjournals.org/clincancerres/article/doi/10.1158/1078-0432.CCR-22-2074/710713/A-Phase-I-II-Trial-of-Oral-SRA737-a-Chk1-Inhibitor
Published by the AACR (American Association for Cancer Research) on 15 November 2022. Looks like there is a promotion drive to get SRA 737 into trials in America and UK? Apologies if already posted.
The Sareum tweet was 4 days ago - the same day as the Business Weekly article -which was well received. The tweet simply repeats the wording that was in the article so don’t know why some here are tending to make such an issue about it.
SRA737 completes promising Phase1/2 trials and then shelved. Amended licence agreement put in place. No progress after 3 years and SRA 737 returned to Cancer Pioneer Fund. I wonder what Cancer Pioneer Fund and Sareum really think about this.
Let’s not overlook that another opportunity beckons for SDC 1801 - as Tim has indicated.
https://genomicc.org/results/covid-drug-baricitinib/
As some have indicated already, Tim was very bullish about the prospects of SDC1801 in Autoimmune. Quote ‘ We believe that SDC1801 has significant potential for superior efficacy in autoimmune disease compared to oral therapies currently AND IN DEVELOPMENT’. So IF this does turn out as planned we should have the Number 1 treatment In the massive autoimmune market - at least 39 potential treatment options for SDC1801 has already been listed by Sareum. That is some statement for Tim to make. OK it is IF but should the results of the phase 1a trial be positive, ie low toxicity and good evidence of efficacy., This will be take off time. Always remember it is IF! But what an exciting share to be in at the moment. Oh and let’s not forget SDC 1802 following on.
RNS statements have to be precise in their terminology. Note ‘’ Subject to Regulatory Approval, we plan to advance our lead candidate SDC1801 into clinical trials shortly’. Dictionary definition of shortly is “ in the immediate future eg we will be arriving shortly’. So news on this should be very near.
Re SRA 737 - might be a blessing in disguise as Sareum and Pioneer fund can now plot its own destiny and avoid the pitfalls in the previous contract. I am expecting a lot of interest in this new opportunity for getting SRA737 into the clinic.
Strange time. It may be just a delay. But dare we start to dream that the “interested parties” that Tim has mentioned in past RNS announcements have now come knocking on his door? Always remember that dreams do not often come true!